Intracellular metabolism and persistence of the anti-human immunodeficiency virus activity of 2′,3′-didehydro-3′-deoxy-4′- ethynylthymidine, a novel thymidine analog

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 11, 2007, Pages 3870-3879

  Paintsil, Elijah ^a   Dutschman, Ginger E ^a   Hu, Rong ^a   Grill, Susan P ^a   Lam, Wing ^a   Baba, Masanori ^b   Tanaka, Hiromichi ^c   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEHYDRO 3' DEOXY 4' ETHYNYLTHYMIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DOXYCYCLINE; PHOSPHOGLYCERATE KINASE; STAVUDINE; THYMIDINE DERIVATIVE; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTI-HIV AGENTS; CELL LINE; DIDEOXYNUCLEOTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HELA CELLS; HIV; HUMANS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; THYMINE NUCLEOTIDES; VIRUS REPLICATION; ZIDOVUDINE;

EID: 35848929439     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00692-07     Document Type: Article

References (54)

1. Balzarini, J. 1994. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 16:113-126.
2. Bardsley-Elliot, A., and C. M. Perry. 2000. Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection. Paediatr. Drugs 2:373-407.
3. Brinkman, K., H. J. ter Hofstede, D. M. Burger, J. A. Smeitink, and P. P. Koopmans. 1998. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12:1735-1744.
4. Cheeseman, S. H., S. E. Hattox, and M. M. McLaughlin. 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37:178-182.
5. Chen, C. H., and Y. C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
6. Chen, C. H., M. Vazquez-Padua, and Y. C. Cheng. 1991. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:625-628.
7. Chun, T. W., L. Carruth, D. Finzi, X. Shen, J. A. DiGiuseppe, H. Taylor, M. Hermankova, K. Chadwick, J. Margolick, T. C. Quinn, Y. H. Kuo, R. Brookmeyer, M. A. Zeiger, P. Barditch-Crovo, and R. F. Siliciano. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387:183-188.
8. Coates, J. A., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
9. Dutschman, G. E., E. G. Bridges, S. H. Liu, E. Gullen, X. Guo, M. Kukhanova, and Y. C. Cheng. 1998. Metabolism of 2′,3′-dideoxy- 2′,3′-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved antihuman immunodeficiency virus beta-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42:1799-1804.
10. Dutschman, G. E., S. P. Grill, E. A. Gullen, K. Haraguchi, S. Takeda, H. Tanaka, M. Baba, and Y. C. Cheng. 2004. Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob. Agents Chemother. 48:1640-1646.
11. Feng, J. Y., E. Murakami, S. M. Zorca, A. A. Johnson, K. A. Johnson, R. F. Schinazi, P. A. Furman, and K. S. Anderson. 2004. Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2′,3′-dideoxy-5-fluoro-3′-thiacytidine- triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob. Agents Chemother. 48:1300-1306.
12. Furman, P. A., J. A. Fyfe, M. H. St Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, et al. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
13. Gathe, J. C., Jr., P. Ive, R. Wood, D. Schurmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18:1529-1537.
14. Gosselin, G., R. F. Schinazi, J. P. Sommadossi, C. Mathe, M. C. Bergogne, A. M. Aubertin, A. Kirn, and J. L. Imbach. 1994. Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1292-1297.
15. Grove, K. L., and Y. C. Cheng. 1996. Uptake and metabolism of the new anticancer compound beta-L-(-)-dioxolane-cytidine in human prostate carcinoma DU-145 cells. Cancer Res. 56:4187-4191.
16. Guay, L. A., P. Musoke, T. Fleming, D. Bagenda, M. Allen, C. Nakabiito, J. Sherman, P. Bakaki, C. Ducar, M. Deseyve, L. Emel, M. Mirochnick, M. G. Fowler, L. Mofenson, P. Miotti, K. Dransfield, D. Bray, F. Mmiro, and J. B. Jackson. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
17. Haraguchi, K., S. Takeda, H. Tanaka, T. Nitanda, M. Baba, G. E. Dutschman, and Y. C. Cheng. 2003. Synthesis of a highly active new anti-HIV agent 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine. Bioorg. Med. Chem. Lett. 13:3775-3777.
18. Hayakawa, H., S. Kohgo, K. Kitano, N. Ashida, E. Kodama, H. Mitsuya, and H. Ohrui. 2004. Potential of 4′-C-substituted nucleosides for the treatment of HIV-1. Antiviral Chem. Chemother. 15:169-187.
19. Hsu, C. H., R. Hu, G. E. Dutschman, G. Yang, P. Krishnan, H. Tanaka, M. Baba, and Y. C. Cheng. 2007. Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro-3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob. Agents Chemother. 51:1687-1693.
20. Hu, R., L. Li, B. Degreve, G. E. Dutschman, W. Lam, and Y. C. Cheng. 2005. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-beta- L-arabinofuranosyl)-5-methyluracil (Clevudine) and 2′,3′- didehydro-2′,3′-dideoxythymidine in cells. Antimicrob. Agents Chemother. 49:2044-2049.
21. Jackson, J. B., S. Barnett, E. Piwowar-Manning, L. Apuzzo, C. Raines, C. Hendrix, F. Hamzeh, and J. Gallant. 2003. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 17:547-553.
22. Johnson, A. A., A. S. Ray, J. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson. 2001. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276:40847- 40857.
23. Kakuda, T. N. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685-708.
24. Kitano, K., S. Kohgo, K. Yamada, S. Sakata, N. Ashida, H. Hayakawa, D. Nameki, E. Kodama, M. Matsuoka, H. Mitsuya, and H. Ohrui. 2004. Attempt to reduce cytotoxicity by synthesizing the L-enantiomer of 4′-C-ethynyl-2′-deoxypurine nucleosides as antiviral agents against HIV and HBV. Antiviriral Chem. Chemother. 15:161-167.
25. Krishnan, P., E. A. Gullen, W. Lam, G. E. Dutschman, S. P. Grill, and Y. C. Cheng. 2003. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J. Biol. Chem. 278:36726-36732.
26. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
27. Lee, H., J. Hanes, and K. A. Johnson. 2003. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719.
28. Lenert, L. A., M. Feddersen, A. Sturley, and D. Lee. 2002. Adverse effects of medications and trade-offs between length of life and quality of life in human immunodeficiency virus infection. Am. J. Med. 113:229-232.
29. Lin, T. S., M. Z. Luo, M. C. Liu, S. B. Pai, G. E. Dutschman, and Y. C. Cheng. 1994. Antiviral activity of 2′,3′-dideoxy-beta- L-5-fluorocytidine (beta-L-FddC) and 2′,3′- dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:171-174.
30. Lin, T. S., M. Z. Luo, M. C. Liu, Y. L. Zhu, E. Gullen, G. E. Dutschman, and Y. C. Cheng. 1996. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-cytidine (beta-L-d4C) and 2′,3′-dideoxy 2′,3′-didehydro- beta-L-5-fluorocytidine (beta-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1757-1759.
31. Longley, M. J., P. A. Ropp, S. E. Lim, and W. C. Copeland. 1998. Characterization of the native and recombinant catalytic subunit of human DNA polymerase gamma: identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity. Biochemistry 37:10529-10539.
32. Maag, H., R. M. Rydzewski, M. J. McRoberts, D. Crawford-Ruth, J. P. Verheyden, and E. J. Prisbe. 1992. Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides. J. Med. Chem. 35:1440-1451.
33. Martin, J. L., C. E. Brown, N. Matthews-Davis, and J. E. Reardon. 1994. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:2743-2749.
34. Medina, D. J., C. H. Tsai, G. D. Hsiung, and Y. C. Cheng. 1994. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob. Agents Chemother. 38:1824-1828.
35. Moyer, T. P., Z. Temesgen, R. Enger, L. Estes, J. Charlson, L. Oliver, and A. Wright. 1999. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin. Chem. 45:1465-1476.
36. Nitanda, T., X. Wang, H. Kumamoto, K. Haraguchi, H. Tanaka, Y. C. Cheng, and M. Baba. 2005. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′- ethynylthymidine in vitro. Antimicrob. Agents Chemother. 49:3355-3360.
37. Peter, K., and J. G. Gambertoglio. 1998. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection. Pharm. Res. 15:819-825.
38. Powderly, W. G. 2002. Long-term exposure to lifelong therapies. J. Acquir. Immune Defic. Syndr. 29(Suppl. 1):S28-S40.
39. Richman, D. D. 1993. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37:1207-1213.
40. Schneider, B., R. Sarfati, D. Deville-Bonne, and M. Veron. 2000. Role of nucleoside diphosphate kinase in the activation of anti-HIV nucleoside analogs. J. Bioenerg Biomembr. 32:317-324.
41. Schneider, B., Y. W. Xu, J. Janin, M. Veron, and D. Deville-Bonne. 1998. 3′-Phosphorylated nucleotides are tight binding inhibitors of nucleoside diphosphate kinase activity. J. Biol. Chem. 273:28773-28778.
42. Schneider, B., Y. W. Xu, O. Sellam, R. Sarfati, J. Janin, M. Veron, and D. Deville-Bonne. 1998. Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides. J. Biol. Chem. 273:11491-11497.
43. Shulman, N., and M. Winters. 2003. A review of HIV-1 resistance to the nucleoside and nucleotide inhibitors. Curr. Drug Targets Infect. Disord. 3:273-281.
44. Siddiqui, M. A., S. H. Hughes, P. L. Boyer, H. Mitsuya, Q. N. Van, C. George, S. G. Sarafinanos, and V. E. Marquez. 2004. A 4′-C-ethynyl- 2′,3′-dideoxynucleoside analogue highlights the role of the 3′-OH in anti-HIV active 4′-C-ethynyl-2′-deoxy nucleosides. J. Med. Chem. 47:5041-5048.
45. Siliciano, J. D., J. Kajdas, D. Finzi, T. C. Quinn, K. Chadwick, J. B. Margolick, C. Kovacs, S. J. Gange, and R. F. Siliciano. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
46. Sosa, N., C. Hill-Zabala, E. Dejesus, G. Herrera, A. Florance, M. Watson, C. Vavro, and M. Shaefer. 2005. Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL). J. Acquir. Immune Defic. Syndr. 40:422-427.
47. Squires, K. E. 2001. An introduction to nucleoside and nucleotide analogues. Antivir. Ther. 6(Suppl. 3):1-14.
48. Tornevik, Y., B. Jacobsson, S. Britton, and S. Eriksson. 1991. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res. Hum. Retroviruses 7:751-759.
49. Waheed, A. A., S. D. Ablan, M. K. Mankowski, J. E. Cummins, R. G. Ptak, C. P. Schaffner, and E. O. Freed. 2006. Inhibition of HIV-1 replication by amphotericin B methyl ester: selection for resistant variants. J. Biol. Chem. 281:28699-28711.
50. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
51. Yang, G., G. E. Dutschman, C. J. Wang, H. Tanaka, M. Baba, K. S. Anderson, and Y. C. Cheng. 2007. Highly selective action of triphosphate metabolite of 4′-ethynyl D4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res. 73:185-191.
52. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292:251-265.
53. Zhu, Y. L., D. E. Dutschman, S. H. Liu, E. G. Bridges, and Y. C. Cheng. 1998. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydrobeta-L(-) -5-fluorocytidine. Antimicrob. Agents Chemother. 42:1805-1810.
54. Zimmerman, T. P., W. B. Mahony, and K. L. Prus. 1987. 3′-Azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:5748-5754.